Daxor to showcase new HFSA clinical data on blood volume analysis in advanced heart failure patients
DXR•Daxor said new independent clinical data on blood-volume measurement in advanced heart failure will be presented at HFSA 2026. The findings are expected to show the test identifies fluid-status patterns missed by standard assessments.
1. Data presentation planned
Daxor said new independent clinical data on blood-volume measurement in advanced heart failure patients is scheduled for presentation at HFSA 2026. The findings are expected to show the test can identify clinically meaningful fluid-status patterns missed by standard assessment methods.
2. Analyzer adoption aim
Management framed the data as support for broader hospital adoption of Daxor’s next-generation Blood Volume Analyzer, with the aim of reducing readmissions. The FDA 510(k)-cleared system is described as a faster workflow tool that uses a smaller blood draw.
